Combined treatment by burosumab and a calcimimetic can ameliorate hypophosphatemia due to excessive actions of FGF23 and PTH in adult XLH with tertiary hyperparathyroidism: A case report

INTRODUCTION: X-linked hypophosphatemia (XLH) is the most prevalent type of heritable fibroblast growth factor 23 (FGF23)-related hypophosphatemic rickets. Recently, anti-FGF23 antibody, burosumab, has become clinically available. We herein report a patient with adult XLH and tertiary hyperparathyro...

Descripción completa

Detalles Bibliográficos
Autores principales: Takashi, Yuichi, Toyokawa, Kyoko, Oda, Naoki, Muta, Yoshimi, Yokomizo, Hisashi, Fukumoto, Seiji, Kawanami, Daiji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9751939/
https://www.ncbi.nlm.nih.gov/pubmed/36531500
http://dx.doi.org/10.3389/fendo.2022.1004624

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9751939/
https://www.ncbi.nlm.nih.gov/pubmed/36531500
http://dx.doi.org/10.3389/fendo.2022.1004624

Ejemplares similares